Abstract2 6 2 7
1 0 some traits 46 . For example, increasing age is associated with higher risk of coronary 2 0 6 artery disease, and higher PRS accelerate this increased risk 47 . Consequently, the age accuracy varies as a function of age across phenotypes is needed. interactions, historical population size dynamics, and other factors will further limit 2 1 6 generalizability for genetic risk scores in an unpredictable, trait-specific fashion 49, 50 .
1 7
Complex traits do not behave in a genetically deterministic manner, with some comparability across globally diverse populations; among psychiatric disorders for 2 2 0 example, whereas schizophrenia has a nearly identical genetic basis across East Previous work has assessed prediction accuracy across diverse populations in several 2 3 7 traits and diseases for which GWAS summary statistics are available. These of global biobanks for quantitative traits as well as diversifying priorities from funding 2 4 0 agencies 55, 56 .
As of yet, multi-ethnic work has been slow in most disease areas 57 , 2 4 1 limiting even the opportunity to assess prediction utility in non-European cohorts. Figure S2 ) 15, 16, [19] [20] [21] [22] . By extension, prediction accuracy from the discovery sample across a range of polygenic traits (Table S4) . We assessed 2 6 2 how prediction accuracy decayed across globally diverse populations for 17
anthropometric and blood panel traits in the UK Biobank (UKBB) when using European-
derived summary statistics (Methods); consistent with previous studies, we find that
relative to European prediction accuracy, genetic prediction accuracy was far lower in
other populations (Figure 3 , notably 1.6-fold lower in Hispanic/Latino Americans, 1.7-the utility of PRS within and across populations for many complex traits are still needed.
These evaluations would benefit from rigorous polygenic prediction accuracy
evaluations, especially for diverse non-European patients [62] [63] [64] . Translational genetic prediction may uniquely exacerbate disparities 3 3 4
Our impetus for raising these statistical issues limiting the generalizability of PRS across
population stems from our concern that, while they are legitimately clinically promising
for improving health outcomes for many biomedical phenotypes, they may have a larger
potential to raise health disparities than other clinical factors for several reasons. The
opportunities they provide for improving health outcomes means they inevitably will and 3 3 9
should be pursued in the near term, but we urge that a concerted prioritization to make considerably by reported ethnicity [67] [68] [69] . Defining ethnicity-specific reference intervals is 3 4 9
clearly an important problem that can provide fundamental interpretability gains with
implications for some major health benefits (e.g. need for dialysis and development of
Type 2 diabetes based on ethnicity-specific serum creatinine and hemoglobin A1C directly with health outcomes independent of ancestry, and many others may have a readily collected population reference. In contrast, PRS are uniformly less useful in understudied populations due to 3 5 8 differences in genomic variation and population history 13, 14 . No analogous solution of
defining ethnicity-specific reference intervals would ameliorate health disparities
implications for PRS or fundamentally aid interpretability in non-European populations. The clinical use and deployment of genetic risk scores needs to be informed by the
issues surrounding tests that currently would unequivocally provide much greater
benefit to the subset of the world's population which is already on the positive end of all, compared to random ( Figure 4F ). They are therefore least likely to benefit from 3 7 1 improvements in precision healthcare delivery from genetic risk scores with existing 3 7 2 data due to human population history and study biases. This is a major concern globally 3 7 3
and especially in the U.S., which already leads other middle-and high-income countries
in both real and perceived healthcare disparities
70
. Thus, we would strongly urge that
any discourse on clinical use of polygenic scores include a careful, quantitative
assessment of the economic and health disparities impacts on underrepresented
populations that might be unintentionally introduced by the use of PRS and raise awareness about how to eliminate these disparities. necessary to accompany calls for more diverse studies; while some already exist in the U.S., including for health insurance and employment opportunities via the Genetic
Information Nondiscrimination Act (GINA), stronger protections in these and other areas 3 8 7 ‡ To maximally benefit all populations, the largest existing GWAS results should be used. Downsampling European GWAS for the sake of parity results in worse predictors for all individuals.
Stanley Global initiatives on the genetics of type II diabetes and psychiatric disorders, To enable progress towards parity, it will be critical that open data sharing standards be European results. Locally appropriate and secure genetic data sharing techniques as 4 5 0 well as equitable technology availability will need to be adopted widely in Asia and equality. All of these efforts are important and should be prioritized not just for risk Individuals whose ancestry is "not reported" are not shown. here are quantitative anthropometric and blood panel traits, as described in Table S1 , E u r o p e a n A m e r i c a n S o u t h A s i a n E a s t A s i a n A f r i c a n between BBJ and UKBB ( higher in the UK Biobank for quantitative traits than in BioBank Japan and vice versa for 
